DE69111642T2 - Gabapentin und dessen Derivate zur Behandlung neurodegenerativer Krankheiten. - Google Patents

Gabapentin und dessen Derivate zur Behandlung neurodegenerativer Krankheiten.

Info

Publication number
DE69111642T2
DE69111642T2 DE69111642T DE69111642T DE69111642T2 DE 69111642 T2 DE69111642 T2 DE 69111642T2 DE 69111642 T DE69111642 T DE 69111642T DE 69111642 T DE69111642 T DE 69111642T DE 69111642 T2 DE69111642 T2 DE 69111642T2
Authority
DE
Germany
Prior art keywords
gabapentin
derivatives
treatment
neurodegenerative diseases
huntington
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69111642T
Other languages
English (en)
Other versions
DE69111642D1 (de
Inventor
Geoffrey Neil Woodruff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27039510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69111642(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of DE69111642D1 publication Critical patent/DE69111642D1/de
Application granted granted Critical
Publication of DE69111642T2 publication Critical patent/DE69111642T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69111642T 1990-01-02 1991-01-02 Gabapentin und dessen Derivate zur Behandlung neurodegenerativer Krankheiten. Expired - Fee Related DE69111642T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45991290A 1990-01-02 1990-01-02
US07/615,151 US5084479A (en) 1990-01-02 1990-11-23 Novel methods for treating neurodegenerative diseases

Publications (2)

Publication Number Publication Date
DE69111642D1 DE69111642D1 (de) 1995-09-07
DE69111642T2 true DE69111642T2 (de) 1996-01-25

Family

ID=27039510

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69111642T Expired - Fee Related DE69111642T2 (de) 1990-01-02 1991-01-02 Gabapentin und dessen Derivate zur Behandlung neurodegenerativer Krankheiten.

Country Status (7)

Country Link
US (1) US5084479A (de)
EP (1) EP0446570B1 (de)
JP (1) JP2903434B2 (de)
AT (1) ATE125701T1 (de)
DE (1) DE69111642T2 (de)
DK (1) DK0446570T3 (de)
HK (1) HK1005166A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
US5217957A (en) * 1991-08-20 1993-06-08 Warner-Lambert Company Cholecystokinin antagonists useful for treating depression
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
US5510381A (en) * 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
CA2244912C (en) * 1996-03-14 2005-07-12 Warner-Lambert Company Novel substituted cyclic amino acids as pharmaceutical agents
US6372792B1 (en) 1996-04-26 2002-04-16 Guy Chouinard Method for treating anxiety, anxiety disorders and insomnia
IL126999A (en) 1996-07-24 2002-03-10 Warner Lambert Co Pharmaceutical preparations containing isobutylgaba and its history for use in the treatment of pain
IL133235A (en) * 1997-06-30 2004-02-19 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexane nmda receptor antagonists and pharmaceutical compositions comprising them
AU9019198A (en) 1997-08-19 1999-03-08 Warner-Lambert Company Methods for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotor stimulants
WO1999018063A2 (en) 1997-10-07 1999-04-15 Warner-Lambert Company Process for preparing a cyclic amino acid anticonvulsant compound
CN1138755C (zh) 1997-10-27 2004-02-18 沃尼尔·朗伯公司 作为药物的环状氨基酸及其衍生物
US6984659B2 (en) 1997-11-18 2006-01-10 Klinikum Der Albert-Ludwigs Universitaet 2-pyrrolidinone derivatives substituted at position 4 for reducing the extracellular glutamate level
DE19751062A1 (de) * 1997-11-18 1999-07-08 Univ Ludwigs Albert An 4-Stellung substituierte 2-Pyrrolidinon-Derivate zur Verringerung des extrazellulären Glutamat-Spiegels
CA2327285C (en) * 1998-05-15 2005-06-14 Warner-Lambert Company Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same
CU23051A3 (es) * 1998-05-15 2005-06-24 Warner Lambert Co Composiciones solidas que contienen derivados de acido gamma-aminobutirico y procesos para prepararlas.
US6294198B1 (en) 1999-08-24 2001-09-25 Purepac Pharmaceutical Co. Pharmaceutical tablet formulation containing gabapentin with improved physical and chemical characteristics and method of making the same
FR2801217B1 (fr) * 1999-11-24 2002-12-06 Aventis Pharma Sa Association de riluzole et de gabapentine et son utilisation comme medicament
US6350768B1 (en) 1999-11-24 2002-02-26 Aventis Pharma S.A. Combination of riluzole and of gabapentin and its use as a medicament
PT1289364E (pt) 2000-06-16 2004-04-30 Teva Pharma Gabapentina estavel contendo mais do que 20 ppm de iao cloreto
CN1447684A (zh) * 2000-06-16 2003-10-08 特瓦制药工业有限公司 具有在可控制范围内的pH值的稳定的加巴喷丁
IL152770A0 (en) * 2000-06-26 2003-06-24 Warner Lambert Co Gabapentin analogues for sleep disorders
US7056951B2 (en) 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
AU2002345638A1 (en) * 2001-06-11 2002-12-23 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
US6818787B2 (en) * 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
ES2380287T3 (es) * 2001-06-11 2012-05-10 Xenoport, Inc. Profármacos de análogos de GABA, composiciones y sus usos
US7186855B2 (en) * 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) * 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US20070184104A1 (en) * 2001-10-25 2007-08-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
TWI312285B (en) * 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
ITMI20012750A1 (it) 2001-12-21 2003-06-21 Procos Spa Processo per la produzione dell'acido 1-(amminometil)-cicloesil-acetico in forma pura
US20030119908A1 (en) * 2001-12-21 2003-06-26 Zambon Group S.P.A. Stable gabapentin compositions
AU2003210486B2 (en) * 2002-01-16 2007-06-28 Endo Pharmaceuticals Inc. Pharmaceutical composition and method for treating disorders of the central nervous system
EP1485082A4 (de) 2002-02-19 2009-12-30 Xenoport Inc Syntheseverfahren für prodrugs von 1-acyl-alkyl derivaten und ihre zusammensetzungen
WO2003089403A1 (en) * 2002-04-16 2003-10-30 Taro Pharmaceutical Industries Ltd. Process for preparing gabapentin
AU2003243180A1 (en) * 2002-05-17 2003-12-12 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
WO2004053192A1 (en) * 2002-12-11 2004-06-24 Xenoport, Inc. Orally administered dosage forms of fused gaba analog prodrugs having reduced toxicity
AU2003297927A1 (en) 2002-12-11 2004-06-30 Xenoport, Inc. Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
WO2005000294A1 (en) * 2003-06-06 2005-01-06 Pharmacia Corporation Selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders
SG146643A1 (en) 2003-09-17 2008-10-30 Xenoport Inc Treating or preventing restless legs syndrome using prodrugs of gaba analogs
KR101096480B1 (ko) 2003-10-14 2011-12-20 제노포트 인코포레이티드 감마-아미노부티르산 유사체의 결정질 형태
WO2005082372A1 (en) * 2004-01-29 2005-09-09 Pfizer Products Inc. COMBINATION OF γ-AMINOBUTYRIC ACID MODULATORS AND 5-HT 1B RECEPTOR ANTAGONISTS
US20050187295A1 (en) * 2004-02-19 2005-08-25 Surendra Kalyan Processes for the preparation of gabapentin
ITMI20040579A1 (it) * 2004-03-25 2004-06-25 Zambon Spa Processo di preparazione di gabapentina
MX2007005306A (es) 2004-11-04 2007-06-11 Xenoport Inc Formas de dosis oral de liberacion sostenida de la prodroga gabapentina.
US20090176882A1 (en) * 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
WO2011151708A1 (en) 2010-06-01 2011-12-08 Rubicon Research Private Limited Gastroretentive dosage forms of gaba analogs
EP2923694B1 (de) 2014-03-27 2018-11-14 Sanovel Ilac Sanayi ve Ticaret A.S. Orale flüssige pharmazeutische lösung von gabapentin
CN114599397B (zh) * 2019-10-25 2024-05-28 国立大学法人京都大学 Tau蛋白病的预防或治疗剂
CN115350172A (zh) * 2022-08-12 2022-11-18 昆明医科大学 Gabapentin对AD情景记忆改善的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel

Also Published As

Publication number Publication date
ATE125701T1 (de) 1995-08-15
DE69111642D1 (de) 1995-09-07
JP2903434B2 (ja) 1999-06-07
EP0446570A2 (de) 1991-09-18
EP0446570B1 (de) 1995-08-02
HK1005166A1 (en) 1998-12-24
US5084479A (en) 1992-01-28
EP0446570A3 (en) 1992-04-01
JPH04210915A (ja) 1992-08-03
DK0446570T3 (da) 1995-11-27

Similar Documents

Publication Publication Date Title
DE69111642D1 (de) Gabapentin und dessen Derivate zur Behandlung neurodegenerativer Krankheiten.
DE60124080D1 (de) Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
UY26813A1 (es) Compuestos para tratar enfermedad de alzheimer
DE60112942D1 (de) Verbindungen zur behandlung der alzheimerischen krankheit
ATE478669T1 (de) Zusammenstellungen und methoden zur behandlung der alzheimerschen krankheit, schäden des zentralnervensystems und entzündlichen erkrankungen
FI904204A0 (fi) Foerfarande foer framstaellning av cykliska aminosyraderivat och mellanprodukter.
ATE343388T1 (de) Pde-v hemmer zur behandlung von morbus parkinson
ATE411026T1 (de) Mittel zur behandlung der alzheimer-krankheit
BR9502707A (pt) Composto composição farmacêutica e método para o tratamento de uma afecção
NO20083956L (no) Prodrugs av GABA-analoger, sammensetninger og anvendelse derav
TW229156B (de)
DE69716810T2 (de) 2,3-Disubstituierte-(5,6)-heteroarylkondensierte-pyrimidin-4-one
ES2194960T3 (es) N-(2-sustituido-3-(2-aminoetil)-1h-indol-5-il)-amidas como nuevos agonistas de 5-ht1f.
ATE526981T1 (de) Verwendung von vegf 165 und homologen zur behandlung von neurologischen störungen
ATE268337T1 (de) C11-carbamate von antibakteriellen makroliden
EA200000242A1 (ru) Применение фанхинона для лечения болезни альцгеймера
DE3854121T2 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
ATE180669T1 (de) Verwendung von pregnanderivaten zur behandlung von tumoren
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
ATE239470T1 (de) Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen
DE69911689D1 (de) Verfahren zur Herstellung von S-Aryl-L-cystein und Derivate
DE69424415D1 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit
DE69916577D1 (de) Azetidincarboxamid-derivate zur behandlung von zns störungen
ATE323690T1 (de) Bicyclische(3.1.0)hexane und verwandte verbindungen
HUT56559A (en) Process for producing ascorbinic acid derivatives and pharma

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee